The phenomenon of enhanced glycolysis in tumours has been acknowledged for decades, but biochemical evidence to explain it is only just beginning to emerge. A significant hint as to the triggers and advantages of enhanced glycolysis in tumours was supplied by the recent discovery that succinate dehydrogenase (SDH) and fumarate hydratase (FH) are tumour suppressors and which associated, for the first time, mitochondrial enzymes and their dysfunction with tumorigenesis. Further steps forward showed that the substrates of SDH and FH, succinate and fumarate, respectively, can mediate a 'metabolic signalling' pathway. Succinate or fumarate, which accumulate in mitochondria owing to the inactivation of SDH or FH, leak out to the cytosol, where they inhibit a family of prolyl hydroxylase enzymes (PHDs). Depending on the PHD inhibited, two newly recognized pathways that support tumour maintenance may ensue: affected cells become resistant to certain apoptotic signals and/or activate a pseudohypoxic response that enhances glycolysis and is conveyed by hypoxia-inducible factor.
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Background

Enhanced glycolysis in cancer cells
Glycolysis is the cytosolic pathway that converts glucose to pyruvate. Under aerobic conditions, pyruvate enters the mitochondria to be oxidized by pyruvate dehydrogenase and enzymes of the tricarboxylic acid (TCA) cycle (Figure 1 ). Although glycolysis and the TCA cycle produce only a small amount of ATP from oxidation of each glucose molecule, two major bioenergetic products, NADH and FADH 2 , result from these processes and, in the presence of oxygen, supply reducing equivalents for ATP synthesis by oxidative phosphorylation. The oxidation of NADH and FADH 2 and the subsequent phosphorylation of ADP to form ATP take place in the inner mitochondrial membrane by the protein complexes (I-IV) of the electron transport chain (ETC) and ATP synthase (complex V) (Figure 1 ). Electron transport from NADH and FADH 2 along the ETC generates a proton gradient across the mitochondrial inner membrane -the mitochondrial membrane potential -that is harnessed by the enzyme ATP synthase to convert ADP þ Pi to ATP, with each molecule of NADH or FADH 2 resulting in three or two molecules of ATP, respectively. Thus, under normal oxygen and glucose conditions and continuous energy requirements, most of the ATP in most cell types is produced by oxidative phosphorylation.
Energy metabolism denotes the reactions from which the cell obtains and expends energy. Although tightly controlled energy metabolism is fundamental to survival, many types of cancer paradoxically exhibit abnormal glycolysis or mitochondrial activity in the face of high growth and proliferation rates. In fact, in cancer cells, ATP can be predominantly derived from glycolysis, a significantly less efficient route of ATP production, compared to oxidative phosphorylation (Gatenby and Gillies, 2004) . When glycolysis prevails, pyruvate is reduced to lactate in order to reoxidize NADH to NAD þ that is required for sustained glycolysis (Figure 1 ). Although this apparently anaerobic glycolysis under aerobic conditions is now widely recognized, its biochemical causes and biological consequences in tumours are not (Gatenby and Gillies, 2004; Zu and Guppy, 2004) . Research to elucidate the mechanisms that lead to enhanced glycolysis in tumours and explain its advantages to their growth and survival will undoubtedly help us target energy metabolism pathways to produce cancer therapeutics.
Increased glycolysis by tumour cells under aerobic conditions could be due to one or more of several mechanisms. Broadly, these can originate from either enhancing signals that directly increase glycolysis or from inhibiting energy metabolism by the mitochondria, rendering glycolysis the major source of ATP. Glycolytic enzymes are induced by oncogenes (Dang and Semenza, 1999; Plas and Thompson, 2005) or by the hypoxia-inducible transcription factor (HIF) (Maxwell, 2005a) , whereas oxidative phosphorylation can be inhibited by mutations in mitochondrial DNA (Carew and Huang, 2002; Modica-Napolitano and Singh, 2004) or a dysfunctional TCA cycle owing to loss of function of mitochondrial tumour suppressor genes (Eng et al., 2003; Gottlieb and Tomlinson, 2005) . This review focuses on a newly discovered biochemical link between the loss of mitochondrial tumour suppressors and the induction of glycolysis by the HIF pathway. It will address the contribution of this and alternative pathways to cancer formation owing to loss of mitochondrial tumour suppressors.
Hypoxia-inducible factor
In many tumours, oxygen availability becomes limited (hypoxia) very quickly during cancer development. Intermittent hypoxia may arguably be the only reason for increased tumour glycolysis (Zu and Guppy, 2004) . The major regulator of the response to hypoxia is the HIF transcription factor. Hypoxia-inducible factor is a heterodimeric complex comprised of HIFa and HIFb subunits (Maxwell, 2005b ). Three genes encode three different a-subunits of HIFa (HIF1a, 2a and 3a) and two genes encode HIFb subunits (HIF1b/ARNT1 and ARNT2), enabling combinatorial complexity and the formation of HIF heterodimers with potentially different activities (Maxwell, 2005b) . Under normal oxygen levels (normoxia), the protein level of HIFa is very low owing to constant degradation, mediated by a sequence of post-translational modification events. The first is HIFa hydroxylation on two prolyl residues, a reaction that is catalysed by HIFa prolyl hydroxylase enzymes (PHD1, 2 and 3 also known as EglN2, 1 and 3, respectively) (Dann and Bruick, 2005) . Following HIFa hydroxylation, the von Hippel-Lindau (VHL) gene product (pVHL) mediates the ubiquitylation of HIFa, leading to proteasome-mediated degradation (Schofield and Ratcliffe, 2005) . Hypoxia-inducible factora hydroxylation by PHD enzymes is oxygen dependent. Figure 1 Schematic representation of the metabolic pathways discussed in this review. Pathways are colour-coded: green -glycolysis; red -tricarboxylic acid (TCA) cycle; blue -oxidative phosphorylation; brown -non-essential amino-acid synthesis; pink -pentose phosphate pathway and nucleotide synthesis; purple -fatty acid synthesis. The fumarate hydratase (FH) and succinate dehydrogenase (SDH) tumour suppressors are also depicted. The SDH complex is involved in both the TCA cycle and oxidative phosphorylation and is coloured accordingly. The anaplerotic reaction mediated by pyruvate carboxylase is indicated here owing to its crucial role in restoring depleted TCA cycle intermediates required for amino and fatty acid synthesis. Electron flow within different complexes of the electron transport chain and the mobile electron carriers quinone and cytochrome c are not depicted in this diagram. Solid arrows indicate direct conversion whereas dotted arrows indicate a general pathway.
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A King et al However, as PHDs possess a high K m for oxygen, HIFa escapes hydroxylation and degradation under hypoxic conditions (Schofield and Ratcliffe, 2004) . Once stabilized, HIFa translocates to the nucleus, where it can heterodimerize with HIFb to form an active HIF transcription factor, leading to the expression of genes involved in, among other mechanisms, glucose metabolism and angiogenesis -both survival responses to hypoxia in normal and malignant tissues (Figure 2 ). Tumour growth and survival depend on the enhancement of both glucose metabolism and angiogenesis. Accordingly, some tumours demonstrate high HIF activity even under normoxic conditions, indicating high tumour resilience and poor patient prognosis (Maxwell, 2005a) . A pseudohypoxic response in tumours can be achieved either by accelerated mammalian target of rapamycin (mTOR)-dependent translation or by impaired degradation of HIFa (Figure 2 ). The mTOR-dependent translation of HIFa is induced by the loss of the Tsc1, Tsc2 or Lkb1 tumour suppressor genes and potentially by activation via the Akt pathway (Inoki et al., 2005; Plas and Thompson, 2005) . Impaired HIFa degradation is severely manifest in cells deficient for the VHL tumour suppressor gene (Kim and Kaelin, 2004) . More recently, impaired HIFa degradation was demonstrated in tumours lacking the tumour suppressors succinate dehydrogenase (SDH) and fumarate hydratase (FH or fumarase), nuclear genes that encode mitochondrial proteins (Isaacs et al., 2005; Selak et al., 2005) .
Mitochondrial tumour suppressor genes
Both SDH and FH are TCA cycle enzymes that convert succinate to fumarate and fumarate to malate, respectively. Succinate dehydrogenase is also a functional member (complex II) of the ETC (Figure 1 ). Surprisingly, although SDH and FH are 'housekeeping genes' with key bioenergetic roles, mutations in these genes cause cancer: mutations in subunits B, C or D of SDH lead to the development of paraganglioma or phaeochromocytoma and mutations in FH cause leiomyoma, leiomyosarcoma or renal cell carcinoma (for more details see Gottlieb and Tomlinson, 2005) .
As many of the genetic aspects of mitochondrial tumour suppressor genes have been discussed in several recent extensive reviews (Baysal, 2003; Eng et al., 2003; Favier et al., 2005; Gottlieb and Tomlinson, 2005) , only a brief history of the field will be given and more current data will be covered in this review. In particular, attention will be given to recent findings concerning the potential mechanisms of tumorigenesis in SDH and FH-linked tumours.
This relatively new field of research opened with a genetic study of the cancer syndrome hereditary paraganglioma (HPGL). Paraganglioma are typically benign tumours derived from neuronal ectoderm cells along the sympathetic or parasympathetic nervous systems (Dahia, 2006) . In 2000, Baysal et al. (2000) discovered that the gene mutated in a particular HPGL syndrome associated with the 11q23 locus (PGL1) is in fact SDHD Figure 2 Hypoxia-inducible factor (HIF)a homeostasis is controlled by its rate of translation and degradation. Under physiologic conditions, HIFa is constantly degraded in a process dependent on oxygen, prolyl hydroxylation (by PHD) and ubiquitylation (mediated by pVHL). In cancer, elevated HIFa levels can be seen owing to hypoxia (lack in oxygen) or pseudo-hypoxia (PHD inhibition or pVHL mutation) that inhibit HIFa degradation or owing to accelerated translation (potentially mediated by Akt or loss of Tsc complex or LKB1). Proteins coloured in green represent HIF downregulators whereas those in red represent HIF inducers. Interestingly, many oncogenes and tumour suppressor genes are involved in HIF regulation either positively or negatively, respectively, emphasizing the importance of HIF in tumour development and/or sustention. Solid arrows indicate direct interaction whereas dotted arrows indicate an indirect pathway.
Succinate dehydrogenase and fumarate hydratase A King et al (Baysal et al., 2000) . Following this initial discovery, it did not take long to identify the genes of two other HPGL-associated loci, PGL4 (1p36) and PGL3 (1q21), to be SDHB and SDHC, respectively (Niemann and Muller, 2000; Astuti et al., 2001) . Germ line heterozygous mutations of these genes generally follow the classic Knudson's 'two hits' sequence of tumour suppressor inactivation and are usually, but not always, associated with loss of heterozygosity (LOH) in the tumours (Pawlu et al., 2005) . Mutations in the SDH tumour suppressor genes are associated not only with familial syndromes but are also observed in sporadic paraganglioma and in phaeochromocytoma, a subtype of paraganglioma derived from catecholamine-secreting chromaffin cells, usually in the adrenal medulla (Gottlieb and Tomlinson, 2005) . The observation that loss of function of the SDH complex is mostly associated with paraganglioma, regardless of the SDH subunit involved, suggests that tumorigenesis because of these mutations stems from a common biochemical pathway. This is supported by the observation that mutations in either SDHB or SDHD result in the disintegration of the SDH complex and a complete loss of SDH enzymatic activity (Gimenez-Roqueplo et al., 2001; Gimenez-Roqueplo et al., 2002; Douwes Dekker et al., 2003) . However, a closer examination of the genotype-phenotype link revealed several differences between the different SDH genes. SDHC mutations or deletions are rare and have so far been associated only with familial and sporadic head and neck paraganglioma (Baysal et al., 2004; Schiavi et al., 2005) . In addition, two comprehensive comparison studies of tumours with SDHB or SDHD mutations have been performed and several obvious differences have been identified (Neumann et al., 2004; Benn, 2006) . It is noteworthy that SDHD mutations are mostly related to head and neck paraganglioma whereas SDHB mutations can be seen at higher frequencies in adrenal and extra-adrenal phaeochromocytoma as well as in non-paraganglioma tumours. SDHB mutations are also associated with higher incidences of malignant and metastatic tumours such as malignant phaeochromocytoma and, in some cases, renal cell carcinoma .
In 2002, the FH gene at 1q43 was independently identified as the fourth mitochondrial tumour suppressor gene in families with the hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome (Tomlinson et al., 2002) . Like the SDH genes, FH mutations lead to loss of function and are associated with loss of the wild-type allele and FH activity in the tumours (Tomlinson et al., 2002; Wei et al., 2006) . Unlike SDH, somatic FH mutations are rare and are restricted to uterus leiomyomas (Lehtonen et al., 2004) .
Mechanisms linking loss of mitochondrial tumour suppressors to cancer
It is important to state that the different types of tumours that develop from the dysfunction of either SDH or FH probably indicate that different mechanisms contribute variably to tumour phenotype. Such mechanisms may also cause the small but significant genotype-phenotype differences observed between the SDH genes. Yet pseudo-hypoxia, the major phenomenon shown to date to mediate the tumorigenic outcome of the loss of mitochondrial tumour suppressors, is a common mechanism for both SDH and FH mutations. Still, the existence of a common mechanism is in keeping with the fact that SDH and FH catalyse successive reactions of the TCA cycle and thus share a common pathway (Figure 1) .
Loss of succinate dehydrogenase and fumarate hydratase causes pseudo-hypoxia and hypoxia-inducible factor induction The link between the loss of mitochondria tumour suppressors and pseudo-hypoxia was indicated by several studies. Initial research by Gimenez-Roqueplo et al. (2001) showed that in some tumours with SDHD or SDHB mutations, the HIF pathway and consequently an angiogenic response are activated. This study explained the high vascular density observed in these paragangliomas. More recently, an extensive gene expression analysis of 76 phaeochromocytomas with different genetic lesions revealed a 'HIF signature' pattern of gene expression in a cluster of phaeochromocytomas with SDHB, SDHD or VHL mutations (Dahia et al., 2005) . Interestingly, in the past year, it was shown that FH-deficient tumours also display high vascularity (Pollard et al., 2005a) , increased HIFa levels and activity (Pollard et al., 2005b ) and increased expression of glycolytic genes (measured by gene profiling) (Vanharanta et al., 2006) . These independent studies collectively suggested that pseudo-hypoxia, manifested by high HIF activity under normoxic conditions, is an important factor that links mitochondrial tumour suppressors and cancer.
Mechanisms of hypoxia-inducible factor induction. The works described above, while linking the loss of mitochondrial tumour suppressors to HIF activation, do not provide a biochemical rationale for the link. The first biochemical explanation was reported in 2005 (Selak et al., 2005) and demonstrated that succinate, the substrate of SDH, can provoke HIF stability. Succinate is a dicarboxylic acid, capable of crossing the mitochondrial inner membrane (the only real barrier to small metabolites in the mitochondria) via the dicarboxylate carrier. Selak et al. (2005) showed that SDH dysfunction in cells raised the levels of succinate and, that succinate serves as an intracellular messenger between the mitochondria and the cytosol. Succinate that accumulates in the mitochondrial matrix owing to SDH dysfunction leaks out into the cytosol where it inhibits the activity of HIFa PHDs. As mentioned above, HIFa prolyl hydroxylation by PHD is the first step in tagging HIFa for degradation, enabling its interaction with pVHL. PHDs are a-ketoglutaratedependent dioxygenases and overall they catalyse the conversion of a prolyl residue, molecular oxygen and a-ketoglutarate to hydroxy-prolyl, carbon dioxide and succinate using ferrous iron and ascorbate as cofactors (Figure 3) . Thus, succinate is not only a substrate for SDH in the mitochondria, but also a product of PHDs (and, one must add, of other a-ketoglutarate-dependent dioxygenases) in the cytosol. Therefore, the accumulated succinate, by feedback inhibition of PHDs, leads to HIFa stabilization and activation of the HIF complex.
Importantly, a second work described a mechanistic link between FH deficiency and HIF activation in HLRCC tumours (Isaacs et al., 2005) . In this work, it was shown that, like succinate (and potentially even better), fumarate, which accumulates in FH-deficient tumours, inhibits PHD activity in the cytosol. Fumarate is not a product of PHD but it is chemically similar to succinate. Structurally, owing to a double bond in the centre of the dicarboxylic acid, fumarate is a rigid molecule compared to succinate. It is possible that due to its structure, fumarate interacts better with PHDs.
Subsequent support for the biochemical role of succinate and fumarate in SDH-and FH-deficient tumours came from metabolomic studies of these tumours (Pollard et al., 2005b) . It was clearly demonstrated that succinate levels are high in SDH-deficient HPGL tumours and that both succinate and fumarate levels are high in HLRCC tumours. The increase in these metabolites coincided with high levels of HIFa protein (Pollard et al., 2005b) . Interestingly, high levels of succinate and the induction of HIF1a was recently described in SDHA-deficient fibroblasts . Although SDHA was not identified as a tumour suppressor, bi-allelic mutations of SDHA were described in Leigh syndrome, an early-onset, progressive neurodegenerative disease cased by defective mitochondrial bioenergetics (Rustin and Rotig, 2002) . This study also addressed the important question as to why SDHA has never been reported to be a tumour suppressor gene and, in particular, why carriers of an SDHA mutant allele (heterozygous parents or siblings of Leigh syndrome patients) do not develop HPGL. Briere et al. (2005) addressed that puzzle by studying the expression of two different (though highly similar) SDHA type I and II genes and showed that, unlike fibroblasts, the paraganglia system expresses both genes. This indicates that for SDHA mutation carriers, the unlikely situation of inactivating three additional alleles, two of which are the intact wild-type alleles of one gene, needs to occur in order to develop HPGL.
Advantages of pseudo-hypoxic tumours. Most tumours eventually reach a hypoxic state and it is conceivable that during rapid proliferation, tumour cells frequently experience intermittent hypoxic conditions. Therefore, tumours that have adapted to an anaerobic state could have a survival advantage. Another aspect of adaptation to hypoxia is HIF-mediated neovascularization, seen in pseudohypoxic tumours such as those with SDH or FH deficiency (see above). This may be important for boosting the nutrient supply needed for tumour survival and growth. Lastly, as mentioned above, HIF plays a major role in the enhanced glycolysis observed in many tumours. In addition to adaptation to anaerobic conditions, enhanced glycolysis is an energetic boost to the cells, rapidly generating ATP in the cytosol. Moreover, enhanced glucose breakdown provides building blocks for the synthesis of nucleotides (via the pentose phosphate pathway), and amino and fatty acids (from glycolytic and TCA cycle intermediates) (Figure 1 ) (Owen et al., 2002) . Even under conditions in which the TCA cycle is not fully functional, as is the case for SDH-and FH-deficient tumours, the anaplerotic reaction catalysed by pyruvate carboxylase, which converts pyruvate to oxaloacetate, can operate to replenish TCA cycle intermediates (Figure 1 ). Further metabolism of oxaloacetate by the TCA cycle generates precursors for many non-essential amino acids and for fatty acids and may provide reducing equivalents for oxidative phosphorylation. These processes are required for the anabolic reactions (protein and DNA synthesis) that lead to growth and proliferation of cancer cells.
Resistance to apoptosis
Whereas under normal conditions they provide the bulk of the energy needed to sustain cell life, mitochondria may also assume the role of executioner: when the elimination of cancer cells is required, either physiologically or therapeutically, mitochondria can trigger apoptosis, the programmed self-destruction of cells (Green and Kroemer, 2005) . Many pro-and anti-apoptotic proteins have been shown recently to affect mitochondrial physiology (Hammerman et al., 2004) . For example, mitochondria-associated hexokinase, a key glycolytic enzyme, confers resistance to apoptosis (Robey and Hay, 2005) . Therefore, defective Figure 3 Hypoxia-inducible factor (HIF)a prolyl hydroxylase (PHD) requires oxygen and a-ketoglutarate as cosubstrates and ferrous iron and ascorbate as cofactors. For that reason, its activity is regulated by oxygen levels and can be inhibited by reactive oxygen species that oxidize its cofactors and by succinate or fumarate, which compete with a-ketoglutarate for binding to the enzyme. Several studies have linked PHD activity to cancer formation owing to the loss of mitochondrial tumour suppressors. Tumour progression owing to PHD inhibition results from high HIF activity or defective apoptosis.
Succinate dehydrogenase and fumarate hydratase A King et al mitochondrial physiology, compensated for by enhanced glycolysis, could possibly render tumour cells apoptosis resistant.
More direct evidence for the role of mitochondrial tumour suppressors in apoptosis has recently emerged from studies of VHL . Generally, VHL disease is a cancer predisposition syndrome caused by the loss of function of pVHL (Kim and Kaelin, 2004) . The tumour pattern of VHL patients includes central nervous system and retinal hemangioblastomas, clear cell renal cell carcinoma and phaeochromocytoma. Lee et al. (2005) focused on specific VHL mutations of type 2C that can cause only phaeochromocytomas and tried to elucidate the cause for their development. Interestingly, type 2C VHL mutants can bind and target HIFa for degradation (Hoffman et al., 2001) . This indicates that, unlike the case of haemangioblastoma and clear cell renal cell carcinoma, mechanisms other than pseudo-hypoxia play a role in phaeochromocytoma development. Lee et al. (2005) found that apoptosis in phaeochromocytoma cells is mediated by c-Jun, which activates PHD3 (EglN3). To activate c-Jun, pVHL eliminates atypical-PKC activity that induces the transcription of JunB, the upstream inhibitor of c-Jun . They also showed that PHD3 is an important target for succinate-mediated inhibition in SDH-deficient cells . They concluded that the block of PHD3-mediated apoptosis is a common pathway for phaeochromocytoma formation in both SDH and VHL mutants. It remains unclear, however, which PHD3 substrates cause the apoptotic response. Although this study did not observe HIF induction in SDH-inhibited cells, it is likely that several targets of PHDs, including HIFa and apoptosis inducing factors, contribute to tumour progression owing to the loss of mitochondrial tumour suppressor genes (Figure 3 ).
Signalling by reactive oxygen species
Apart from the metabolic signalling, which is mediated by succinate and fumarate, other mitochondria-derived molecules have been suggested to trigger the oncogenic signal. These are reactive oxygen species (ROS), which can be generated by the ETC, especially in complex I and III (Raha and Robinson, 2000) . The role of ROS in the pathogenesis of HPGL and HLRCC is still being debated. Structural and functional analysis of SDH (complex II) from Escherichia coli did indicate the potential of ROS production on the SDHA site (Yankovskaya et al., 2003) . This, however, required a block in the electron flow from the FAD site on SDHA to the iron-sulphur centres on SDHB and further to the quinone attached to SDHC and SDHD. It seems likely that when tumorigenic mutations in the SDH subunits occur, succinate may still be oxidized to fumarate, but electrons accumulate on FAD and are then transferred to molecular oxygen to generate superoxide. This was in fact shown to occur in a specific SDHC mutant (mev-1) of the Caenorhabditis elegans nematode (Ishii et al., 1998; Senoo-Matsuda et al., 2001 ). This initial work was extended to a mammalian system, in which NIH3T3 mouse fibroblasts were transfected with a murine mutant of SDHC equivalent to the mev-1 mutant, and high levels of ROS accompanied by increased nuclear DNA mutagenesis were detected (Ishii et al., 2005) .
Interestingly, in addition to mutagenesis, ROS may have another role in the pathology of these tumours. Reactive oxygen species were reported to inhibit PHD activity under normoxic conditions by oxidizing the PHD cofactors ferrous iron and ascorbate (Figure 3 ) (Gerald et al., 2004) . It is therefore tempting to speculate that ROS also play a role in the pseudohypoxic response of SDH (and maybe FH)-deficient tumours.
Despite the observations described above, and for the reasons listed below, it is likely that the role of ROS in the pathology of FH-and SDH-deficient tumours is restricted to specific mutations in SDHC. The majority of tumours derived from SDHB or SDHD mutations have a very weak to non-detectable activity of SDH (Gimenez-Roqueplo et al., 2001; Gimenez-Roqueplo et al., 2002; Douwes Dekker et al., 2003) . This indicates that the SDH complex in these tumours is incapable of oxidizing succinate, a required enzymatic reaction for ROS generation. Moreover, in two recent studies, induced HIF1a but no signs of redox stress were identified in tumours with FH mutations or in SDHAmutated fibroblasts Pollard et al., 2005b) . As carriers of SDHC mutations exhibit a phenotypic profile different to carriers of SDHB or SDHD mutations (Schiavi et al., 2005) , it is possible that ROS generation has a role in determining phenotypic outcomes in these tumours.
Open questions and future directions
In the relatively short time since the discovery of mitochondrial tumour suppressors, vast genetic and biochemical knowledge has accumulated to help elucidate the pathways leading to tumorigenesis. But, as is usually the case, we still have more questions than answers. The metabolic signalling pathway mediated by succinate or fumarate points to a common tumorigenic cause in SDH-or FH-deficient cells. This is in line with the physiological role of these enzymes in the TCA cycle. However, this metabolic signalling pathway does not explain the different tumour types that develop owing to mutations in either protein. Despite their shared metabolic pathway, two major biochemical differences can help to tell SDH-and FH-mediated tumorigenesis apart. Succinate is the prime metabolite to inhibit PHD in SDH-deficient cells, whereas fumarate seems to be the chief inhibitor in FH-deficient cells. Although both molecules were shown to mediate HIF induction (Isaacs et al., 2005; Selak et al., 2005) , it is possible that they inhibit different PHDs with different efficiency. In line with this idea, it was shown that fumarate is a better inhibitor of PHD2 than succinate (Isaacs et al., 2005) . As PHD2 is the major HIFa hydroxylase, this may suggest that pseudo-hypoxia is more profound in FH-deficient tumours. It is possible however, that fumarate cannot match succinate in inhibiting PHD3-dependent apoptosis, as is the case in phaeochromocytoma . Moreover, whereas both enzymes catalyse sequential reactions in the TCA cycle, SDH is also part of the ETC. As discussed above, transporting electrons is a risky business and therefore, despite the lack of a clear redox stress signature in SDHB-and SDHD-deficient tumours, it is still important to thoroughly explore the role of ROS in these tumours.
The importance of PHD in tumours derived from SDH or FH mutations is obvious. Moreover, by examining the different pathways described in Figure 2 , it appears that some tumour suppressor genes have a curtailing effect on HIF activity. This strongly emphasizes the role that HIF plays in oncogenesis. Moreover, it may suggest that PHDs themselves are tumour suppressors though to date, there is no evidence of that. This may be due to a degree of redundancy in the activity of different PHDs. Interestingly, recent studies have identified specific familial mutations in PHD2 and pVHL, each of which leads to erythrocytosis associated with HIF induction, but none of which is associated with cancer (Ang et al., 2002; Percy, 2006) . Perhaps, cancer in these cases is avoided because HIF induction is relatively low (this was not yet evaluated) or because pseudo-hypoxia alone is insufficient to induce tumorigenesis. The latter hypothesis is supported by the observation that mice transgenic for a non-degradable cutaneous HIF1a mutant were not reported to develop tumours (Elson et al., 2001) .
It is apparent that the tumorigenic effect of SDH or FH mutations involves more than one mechanism. Most of the data available today indicate that succinate-or fumarate-mediated inhibition of PHDs is fundamental to this process, but PHD inhibition engages more than one downstream pathway. This might complicate translating our knowledge into an effective treatment. Although HIF, a downstream target of some PHDs, is a very attractive target for treating cancer in general (Hewitson and Schofield, 2004) and several inhibitors have already been tested in preclinical trials (Kung et al., 2004; Welsh et al., 2004; Chau et al., 2005) , HIF may only play a supportive rather than a definitive role in the formation or maintenance of these tumours. The role of PHD3 in apoptosis has not been fully elucidated and so downstream candidates for therapeutic targeting have not been identified. However, as PHD inhibition by succinate and fumarate is accomplished by competing with a-ketoglutarate (Figure 3) , it could be desirable to therapeutically deliver enough a-ketoglutarate into cells to alleviate PHD inhibition and potentially induce tumour cell death.
